Consent to the Distribution of Changed Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Lamivudine 150 mg Tablet, film coated Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom 3TC Lamivudine 10 mg/mL Solution, oral Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom 3TC Losartan potassium 12.5 mg, 50 mg Tablet, film coated Merck Sharp & Dohme Limited, Cramlington, Northumberland, England Cozaar Carvedilol 3.125 mg, 6.25 mg, 12.5 mg, 25 mg Tablets Boehringer Mannheim GmbH., Mannheim, Germany Dilatrend Recombinant human erythropoietin 2000IU, 3000IU, 4000IU, 10000IU (phosphate buffered) Injection, solution, pre-filled syringe Cilag AG., Schaffhausen, Switzerland; Janssen Pharmaceutica nv., Beerse, Belgium and Vetter Pharma-Fertigung GmbH. & Co KG., Ravensburg, Germany Eprex Recombinant human erythropoietin 1000IU, 2000IU, 3000IU, 4000IU, 10000IU (citrate buffered) Injection, solution, vial F Hoffmann-La Roche Limited, Switzerland; and Janssen Pharmaceutica nv., Beerse, Belgium Eprex Dated this 29th day of September 1998. G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.